Bispecific KSI-101 restores barrier resistance from pre-existing insult greater than anti-IL-6 or anti-VEGF monotherapies alone KSI-101 restores barrier integrity to no exposure levels HUVEC cells were treated as indicated after growth to establish barrier Exposure to VEGF + IL-6/R Preclinical model of endothelial cells simulating the blood-retinal barrier Anti-VEGF and anti-IL-6 monotherapy only partially restore barrier function 0 20 40 60 0 50 100 150 Hours % Resistance 150 100 50 0 0 20 40 60 No Exposure to VEGF + IL-6/R: high barrier resistance due to intact tight junctions + VEGF + IL-6/R KSI-101 + VEGF + IL-6/R Anti-VEGF + VEGF + IL-6/R Anti-IL-6 Treatment Exposure Start (Exogenous VEGF + IL-6) % Resistance Hours 54